Handelsavisen
prelaunch
Companies Healthcare VIJP.NS
VI
VIJP.NS NSE (India) Pharmaceuticals

Vijp.Ns

$98,10
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
13,2 %
ROE
14,9 %
Net margin
4,1 %
Debt / equity
0,68
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
14,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VIJP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VIJP.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a debt-to-equity ratio of 0.68, indicating a moderate reliance on debt financing. Its liquidity position is assessed as medium, with a current ratio of 1.9, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -78,871,000 INR, which may raise concerns about its ability to fund operations without external financing.

    In terms of profitability, the company's return on equity (ROE) is 14.91%, and its return on assets (ROA) is 8.39%. These figures are relatively strong, but they should be compared to the industry median to determine if the company is outperforming or underperforming its peers. The company's net income of 47,954,300 INR and operating income of 155,149,000 INR indicate a healthy level of profitability, although the gross profit of 182,262,000 INR suggests that the company may be facing margin pressures.

    The company's revenue is concentrated in a single business segment, as no segment-specific data is provided. Geographically, the company's exposure is not detailed in the available data, but the lack of segment information implies that the company may not have a diversified geographic or product portfolio. This concentration could pose a risk if the company's primary market or product line experiences a downturn.

    The company's growth trajectory is not clearly defined in the available data. The financial snapshot does not provide historical revenue data to assess growth trends. However, the company's free cash flow of 47,338,300 INR and capital expenditure of -7,531,000 INR suggest that the company is generating positive cash flow and is not heavily investing in new projects. This could indicate a mature business with limited growth opportunities or a company that is prioritizing debt reduction and shareholder returns.

    The company's risk assessment highlights a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates that the company's cash reserves are insufficient to cover its long-term debt obligations. This could lead to increased financial stress if the company is unable to generate positive cash flow or secure additional financing. The dilution risk is low, as the number of shares outstanding is the same for both basic and diluted shares, suggesting that there is no significant potential for share dilution.

    Recent events and filings are not detailed in the available data, but the company's financial performance and risk profile suggest that it may be facing challenges in maintaining its liquidity and profitability. The company's negative operating cash flow and reliance on debt financing could be areas of concern for investors and analysts. The lack of segment and geographic data also limits the ability to assess the company's diversification and exposure to different markets.

    Key takeaways
    • The company has a moderate debt-to-equity ratio of 0.68, indicating a balanced capital structure.
    • The company's return on equity (14.91%) and return on assets (8.39%) are strong, but should be compared to industry medians for a complete assessment.
    • The company's revenue and geographic exposure are not detailed, suggesting a potential concentration risk.
    • The company's negative operating cash flow and reliance on debt financing could pose liquidity challenges.
    • The company's free cash flow of 47,338,300 INR indicates that it is generating positive cash flow, but the capital expenditure is minimal.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $98,10
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $321.7M
    Net cash
    -$186.7M
    Current ratio
    1.9
    Debt / equity
    0.7
    ROA
    8.4%
    ROE
    14.9%
    Cash conversion
    -164.0%
    CapEx / revenue
    -0.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin13,2 %Above median
    Net Margin4,1 %Above median
    ROE14,9 %Above P75
    Capex / Rev-0,6 %Above P75
    D/E0,68Bottom quartile
    Cash Conv-1,64Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • VIJP.NS Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VIJP.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage